Related Experiment Videos
[Biochemical modulation of 5-FU with interferon].
1Dept. of Gastroenterology Saitama Cancer Center, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 1, 1992
Summary
This review examines the combination therapy of 5-fluorouracil (5-FU) and interferon (IFN) in phase II clinical trials. It details the treatment protocol and explores the biochemical mechanisms of action, including thymidylate synthase (TS) and thymidine kinase (TK).
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Phase II clinical trials reviewed the combination of 5-fluorouracil (5-FU) and interferon (IFN).
- The established treatment regimen involved specific administration schedules for both 5-FU and IFN.
- The precise mechanisms of action for this combination therapy require further elucidation.
Purpose of the Study:
- To review phase II clinical trials of 5-FU and IFN combination therapy.
- To detail the biochemical mechanisms of action, focusing on thymidylate synthase (TS) and thymidine kinase (TK).
- To discuss the side effects of IFN/5-FU and the dual modulation with leucovorin (LV).
Main Methods:
- Review of phase II clinical trial data.
- Biochemical analysis of drug mechanisms, specifically TS and TK inhibition.
- Compilation of reported side effects and modulation strategies.
Main Results:
- The study outlines a specific administration protocol for 5-FU and IFN.
- Biochemical mechanisms involving TS and TK were explored.
- Side effects and potential dual modulation strategies were referenced.
Conclusions:
- The combination of 5-FU and IFN has been investigated in phase II trials.
- Biochemical pathways involving TS and TK are implicated in the drug's action.
- Understanding side effects and modulation is crucial for clinical application.